Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Immunosuppression for inflammatory bowel disease does not influence Epstein–Ba...
Journal Information
Vol. 42. Issue 9.
Pages 542-547 (November 2019)
Share
Share
Download PDF
More article options
ePub
Visits
3
Vol. 42. Issue 9.
Pages 542-547 (November 2019)
Original article
DOI: 10.1016/j.gastre.2019.03.022
Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term
La inmunosupresión no modifica la carga viral del virus de Epstein-Barr a corto plazo en los pacientes con enfermedad inflamatoria intestinal
Visits
...
Iago Rodríguez-Lagoa,
Corresponding author
iago.r.lago@gmail.com

Corresponding author.
, Olga Merinob, María José López de Goicoecheac, Maitane Aranzamendid, Leire Zubiaurree, Nerea Murof, Jone Ortiz de Zárateg, Gustavo Cillah, José Luis Cabriadaa
a Hospital de Galdakao, Gastroenterology Department, Galdakao, Spain
b Hospital Universitario de Cruces, Gastroenterology Department, Barakaldo, Spain
c Hospital de Galdakao, Microbiology Department, Galdakao, Spain
d Hospital Universitario de Cruces, Microbiology Department, Barakaldo, Spain
e Hospital de Mendaro, Gastroenterology Department, Mendaro, Spain
f Hospital Universitario Donostia, Gastroenterology Department, San Sebastián, Spain
g Hospital Universitario de Basurto, Gastroenterology Department, Bilbao, Spain
h Hospital Universitario Donostia, Microbiology and CIBERES, San Sebastián, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Patient characteristics.
Abstract
Introduction

Immunomodulators and biologics are two of the main drugs used for the treatment of inflammatory bowel disease (IBD). Some of these agents have been associated with certain infections and lymphoproliferative disorders, including Epstein–Barr virus (EBV) infection. Our aim was to determine the influence of immunosuppression in the EBV viral load in patients with IBD.

Materials and methods

We prospectively included naïve patients with IBD who were starting immunosuppressive therapy in four IBD Units. All patients were assessed at baseline and four months after starting immunosuppression for clinical disease activity, biomarkers, EBV serology (IgM VCA, IgG VCA and IgG EBNA) and viral load.

Results

Thirty-two patients were included. At baseline, all patients showed positive results for IgG VCA or IgG EBNA with undetectable EBV viral load. No patient showed detectable EBV viral load after starting the immunosuppressive therapy.

Conclusion

Immunosuppression did not influence on EBV viral load in the short-term in naïve IBD patients.

Keywords:
Inflammatory bowel disease
Epstein–Barr virus
Immunosuppression
Abbreviations:
IBD
CD
UC
EBV
IQR
VCA
EBNA
TNF
CRP
mL
Resumen
Introducción

Los fármacos inmunomoduladores y biológicos son algunos de los tratamientos usados con más frecuencia en la enfermedad inflamatoria intestinal (EII). Algunos de ellos se han relacionado con un mayor riesgo de infecciones o síndromes linfoproliferativos, entre los que se encuentra el virus de Epstein-Barr (VEB). Nuestro objetivo era determinar la influencia a corto plazo de la inmunosupresión sobre la carga viral en pacientes con EII.

Material y métodos

Incluimos de forma prospectiva pacientes con EII en los que se iniciaba algún tratamiento inmunosupresor en 4 hospitales. Todos los pacientes fueron evaluados en el momento de iniciar el tratamiento y 4 meses después de iniciarlo, mediante la actividad clínica, los biomarcadores, la serología del VEB (IgM VCA, IgG VCA e IgG EBNA) y su carga viral.

Resultados

Se incluyeron 32 pacientes, observando en todos ellos una serología positiva para IgG VCA o IgG EBNA, con una carga viral indetectable. No se observó ninguna muestra con carga viral detectable durante el seguimiento.

Conclusión

La inmunosupresión no influye sobre la carga viral del VEB a corto plazo en pacientes con EII.

Palabras clave:
Enfermedad inflamatoria intestinal
Virus de Epstein-Barr
Inmunosupresión

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos